相关实验视频

Updated: Jul 8, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

埃泽蒂米布和动脉样硬化心血管疾病:系统性审查和元分析

Fatemeh Omidi¹, Maryam Rahmannia², Amir Hashem Shahidi Bonjar³

¹Department of Cardiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Frontiers in cardiovascular medicine

|December 11, 2023

概括

添加ezetimibe 于他类药物治疗显著降低了LDL-C,并减少了动脉样硬化心血管疾病患者的密集化. 这种组合为管理心血管风险提供了更有效的方法.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
医学研究医学研究

背景情况:

患有动脉样硬化心血管疾病 (ACD) 的人面临心血管事件的风险增加.
降低低密度脂蛋白胆固醇 (LDL-C) 对于减轻这些风险至关重要.
埃泽胺对LDL-C和冠状动脉斑块组成的影响需要更新的元分析.

研究的目的:

进行对以谢胺在降低LDL-C的有效性进行系统性审查和元分析.
为了研究ezetimibe对冠状动脉动脉硬性斑块组成的影响,在ACD患者中.
提供最新评估埃泽胺在心血管疾病管理中的作用.

主要方法:

来自MEDLINE,EMBASE和Cochrane CENTRAL的随机对照试验的系统审查.
包括2023年8月1日之前发表的研究.
使用加权平均差异 (WMD) 和95%置信区间 (CI) 的元分析.

主要成果:

与他类药物相结合的埃泽蒂比单独使用他类药物 (p=0.0001) 显示出更大的LDL-C降低 (-14.06 mg/dl).
亚组分析表明,以谢胺的干预措施有效地降低了密集化 (DC) 量.
最终分析中包括了20项符合条件的研究.

结论:

当与他类药物一起使用时,ezetimibe提供了适度但显著的额外LDL-C降低.
在ACD患者中,ezetimibe显著降低了密集化体积.
需要进一步的研究,以充分了解埃泽胺对斑块组成的影响.

关键词:

心血管疾病心血管疾病埃塞蒂米贝贝是什么意思低密度脂蛋白胆固醇是低密度的脂蛋白胆固醇.这是一个元分析.系统性审查系统性审查

更多相关视频

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Assessment of the Cardiovascular System I: Subjective Data

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...